story of the week
Neoadjuvant Trastuzumab, Pertuzumab, and Chemotherapy vs Trastuzumab Plus Pertuzumab in HER2+ Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Neoadjuvant Trastuzumab, Pertuzumab, and Chemotherapy Versus Trastuzumab Emtansine Plus Pertuzumab in Patients With HER2-Positive Breast Cancer (KRISTINE): A Randomised, Open-Label, Multicentre, Phase 3 Trial
Lancet Oncol 2017 Nov 23;[EPub Ahead of Print], SA Hurvitz, M Martin, WF Symmans, KH Jung, CS Huang, AM Thompson, N Harbeck, V Valero, D Stroyakovskiy, H Wildiers, M Campone, JF Boileau, MW Beckmann, K Afenjar, R Fresco, HJ Helms, J Xu, YG Lin, J Sparano, D SlamonFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.